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INTRODUCTION
other countries, [9] [10] [11] this was paralleled with a decrease in breast cancer incidence, which can however not be firmly attributed to the drop in MHT use. 12 MHT, as the most effective treatment to alleviate menopausal symptoms, 13 is still often used, and several issues regarding its health risk/benefit ratio remain unresolved.
Of them is whether different modalities of use bear different risks. Regarding breast cancer, epidemiologic evidence suggests that this may be the case. For example, in a French cohort study, it was found that combined MHT containing progesterone or dydrogesterone were associated with a lower breast cancer risk than MHT containing other progestagens; 14 a German case-control study found differences between continuous combined and sequential therapies as well as between different types of progestagens, but suggested that the effective progestagenic dose was in fact driving these differences in risk. 15 In Scandinavian countries, the associations observed between estrogenprogestagen use and breast cancer risk have been generally particularly marked. 16 One should seek the reasons for this observation. This implies at least knowing in details the characteristics of MHT use in these countries, in order to contrast them with those in other countries.
Moreover, to date, relatively little information has been available on the recent evolution of MHT use in Scandinavian countries. Such knowledge may be very useful to interpret possible changes in the national incidence of breast cancer (or other diseases).
Using data from a large cohort study of Swedish women with information on lifetime We also aimed at characterizing the modalities of MHT use in this country.
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METHODS
The Women's Lifestyle and Health Cohort Study
As described previously, 17 The Swedish Data Inspection Board and the regional Ethical Committee approved the study.
Assessment of menopausal status; population for analysis
The present study describes MHT use among postmenopausal women. Menopausal otherwise.
Statistical methods
All the statistical analyses were performed using SAS software, version 9.1 (SAS Institute Inc, Cary, NC). Prevalence of MHT use at a given time point was calculated as the number of women who were (currently) using MHT at that time divided by the number of women who were postmenopausal at that time, multiplied by 100. Current MHT use at a given date (month/year) was defined as an MHT being in use at the start of the considered month. Table 2 ).
RESULTS
The reasons for starting MHT are shown in Table 3 (Table 4 ). The reasons most often cited by women were that they felt that the treatment was not needed anymore, or that they worried about side effects. (Table 5) .
When opposed with a progestagen, medium-potency estrogens consisted mainly in oral estradiol. By contrast, when used alone, they often consisted in patches of estradiol, closely followed with oral estradiol (Table 5 ).
The mean cumulative monthly dose of MPA used in oral continuous combinations was 140 mg, and 279 mg in oral sequential combinations. The mean cumulative monthly dose of NETA used in oral continuous combinations was 24.2 mg, and 12.6 mg in oral sequential combinations (data not tabulated).
Finally, the mean age at MHT start was 48. likely explanation is that strong doubts regarding a protective effect of MHT on coronary heart disease emerged from 1998, when the Heart and Estrogen/progestin Replacement Study could not find the expected secondary preventive effects of MHT. 24 We also found that prevention of osteoporosis became less often a reason for starting MHT, although its ability to increase bone mineral density was known for long and its ability to reduce the risk of fracture was demonstrated with the Women's Health Initiative trial. 1 There exist other treatments that are efficient to prevent osteoporosis, such as bisphosphonates, which are becoming easier to use and increasingly popular. 25 As a likely consequence, in a study performed among Swedish gynecologists, 25% in 2003 stated that risk factors for osteoporosis were absolute indications for MHT, versus 60% in 1996. 19 Worry about side effects was a frequently cited reason for stopping in 2003 but also just before 2002. This is likely explained by the fact that the results of studies suggesting an increased risk of breast cancer with MHT use have been publicized since 1997, with the release of an important meta-analysis. 26 As a result, in a study performed among women living in the city of Göteborg, in 1998, two-thirds of the women thought that the risk of breast cancer increased due to MHT use. 20 From that time on, growing evidence has accumulated, showing an increase in breast cancer risk associated with the use of MHT, especially estrogen-progestagen combinations. 27 One of the limitations of our study is that data on MHT use were self-reported, and Lifestyle and Health cohort, should be encouraged so that epidemiological studies will be able to disentangle the effects on the risk of diseases (such as breast cancer) of various treatment parameters, such as molecule, dosage, and timing of initiation. 
